Background Co-trimoxazole prophylaxis can reduce mortality from untreated HIV infection in Africa; whether benefi ts occur alongside combination antiretroviral therapy (ART) is unclear. We estimated the eff ect of prophylaxis after ART initiation in adults.
Introduction
Co-trimoxazole (trimethoprim-sulfamethoxazole) is a widely available, off -patent, low-cost antibiotic that is used in resource-limited settings to treat and prevent community-acquired infections.
Although not recommended as malaria prophylaxis, similar to pyrimethamine-sulfadoxine, it also has antimalarial activity. 1 In HIV infection, it is highly eff ective for treatment of and prophylaxis against Pneumocystis jirovecii pneumonia, 2 Toxoplasma gondii, 3 and Isospora belli. 4, 5 Results of clinical trials and observational studies in HIV-infected, combination antiretroviral therapy (ART)-naive adults and children across Africa have shown that co-trimoxazole prophylaxis reduces mortality, morbidity, and hospital admissions, [4] [5] [6] [7] [8] [9] [10] even in areas of high background bacterial resistance. WHO guidelines recommend that co-trimoxazole prophylaxis is given to all symptomatic adults with CD4 counts lower than 350 cells per μL in resourcelimited settings. 11 Routinely used with ART in high-income countries, cotrimoxazole prophylaxis is usually discontinued when CD4 count exceeds 200 cells per μL because the primary goal is prevention of P jirovecii pneumonia. 12, 13 Despite WHO guidelines, co-trimoxazole has been poorly used with ART in resource-limited settings; and data for its benefi ts (in addition to those of ART), toxic eff ects, and eff ect on ART adherence are scarce. In only one large retro spec tive cohort study in Malawi, investigators reported a 41% reduction in mortality during the fi rst 6 months after ART initiation in clinics providing co-trimoxazole prophylaxis. 14 Participants in the Development of Anti-Retroviral Therapy in Africa (DART) trial 15 had variable exposure to co-trimoxazole; prophylaxis was neither routine nor randomised, but was initiated or continued at discretion of the treating clinician. We aimed to estimate the causal eff ect of co-trimoxazole prophylaxis on survival, WHO stage 3 and 4 events, malaria, CD4 cell count, body-mass index (BMI), and haematological indices in adults after initiation of ART.
Methods

Study design and participants
In our observational analysis, we used data from the randomised DART trial 15 At enrolment all participants started triple-drug combination ART (coformulated zidovudine-lamivudine [GlaxoSmithKline, Ware, UK] plus tenofovir disoproxil fumarate [Gilead Science, Foster City, CA, USA], abacavir [GlaxoSmithKline, Ware, UK], or nevirapine [Boehringer Ingelheim, Ingelheim, Germany]). Participants attended study clinics every 4 weeks, when nurses administered standard symptom and adherence checklists and dispensed prescriptions. Participants could be referred to a doctor at any time and were asked to return to the clinic if they felt unwell between visits. All participants saw a doctor and had a full blood count, lymphocyte subsets, and liver and renal function tests at weeks 4 and 12, then every 12 weeks. All results for LCM participants were returned to clinicians, whereas for CDM participants, haematology and biochemistry results were returned only if requested for clinical reasons or if grade 4 toxic eff ects were reported (protocol safety criteria, grades defi ned in protocol according to minor modifi cations of the AIDS Clinical Trials Group criteria 16 ) and lymphocyte subsets were never returned.
Co-trimoxazole was taken once daily (800 mg sulfamethoxazole, 160 mg trimethoprim). Use of other non-ART drugs (prescription and indication) and malaria episodes (clinical or microscopic diagnosis) were recorded at every doctor visit. Structured summaries for all reported WHO 2003 stage 4 events 17 and deaths were reviewed by an endpoint review committee, who were masked to monitoring strategy and CD4 cell count.
137 (4%) participants who entered a non-randomised pilot study of structured treatment interruptions were excluded. A further 813 participants with CD4 counts of 300 cells per μL or higher were randomly allocated at 52 or 76 weeks to interrupted treatment cycles of 12 weeks on and 12 weeks off ART or to stay on continuous therapy. 18 We excluded follow-up after substudy randomisation for interrupted treatment participants and upweighted it in those receiving continuous treatment (ie, continuous treatment participants were given sampling weights (of roughly two) so that they represented interrupted-treatment participants after censoring, in addition to themselves), assuming comparability of treatment groups at substudy randomisation. Patients gave written consent for screening and, if eligible, enrolment. DART was approved by research ethics committees in Uganda, Zimbabwe, and the UK.
Statistical analysis
All analyses were done with Stata (version 10.0). We used marginal structural models 19 to estimate causal eff ects of co-trimoxazole prophylaxis on outcomes. These models adjusted for time-dependent covariates with inverseprobability treatment weights and were appropriate in the presence of time-dependent covariates (such as BMI) that might be associated with both prescription of co-trimoxazole and outcomes (time-dependent confounders), and could also be aff ected by past co-trimoxazole prophylaxis (webappendix).
DART was registered, number ISRCTN13968779.
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OR=odds ratio. ART=antiretroviral therapy. *Risk of fi rst event or episode estimated from weighted logistic regression models adjusting for length of time on ART with cubic splines, centre, randomised monitoring group, randomisation year, age, sex, WHO stage, and ART prescription at randomisation together with baseline and time-varying values of CD4 cell count, haemoglobin concentration, body-mass index, a WHO stage 3 or 4 event in the previous 4 weeks or since randomisation, and randomisation into a structured treatment interruption (STI) substudy (never, to continuous therapy [CT] 15 STI/CT substudy and were upweighted in analyses. ||p values for test of heterogeneity between centres were 0·85, 0·37, 0·07, and 0·68, for death, stage 4 events, stage 3 or 4 events, and malaria, respectively. **p values for test of heterogeneity in eff ect of co-trimoxazole prophylaxis between never users, used more than 12 weeks ago, and used in the past 12 weeks were 0·28, 0·02, 0·36, and 0·02. † †p values for test of heterogeneity in eff ect of co-trimoxazole prophylaxis between present users by duration of consecutive use (1-12, 12-24, >24 weeks) were 0·21, 0·46, 0·42, and 0·87. ‡ ‡p values for test of heterogeneity between time periods were 0·06, 0·76, 0·50, and 0·31. Participants had variable exposure to co-trimoxazole; prophylaxis was never prescribed during follow-up for 324 (10%) participants, 1959 (62%) were taking it at ART initiation, and 896 (28%) started while on ART, with median 3·5 years (0·9-4·5) total use post-ART in those ever starting. Use at ART initiation varied with centre, year of randomisation, and initial combination treatment. Of 368 participants who died before end of follow-up, only 25 (7%) did not have complete co-trimoxazole history before death and were censored at their last clinic visit. 8128 (57%) person-years of follow-up were spent on cotrimoxazole. Use of prophylaxis diff ered substantially between the four centres (15%, 72%, 72%, 79%). Only 105 (<1%) person-years of follow-up were spent off ART. Reported ART adherence was high both in participants currently on and off co-trimoxazole, with no missed doses in the past 4 weeks reported at 5234 (83%) and 2426 (78%) visits, respectively, in the fi rst 12 weeks, at 19 688 (93%) and 19 415 (87%) visits in weeks 12-72, and at 65 669 (93%) and 39 965 (91%) visits at more than 72 weeks of ART, excluding visits after randomisation to structured treatment interruptions.
Exclusion of follow-up after randomisation to structured treatment interruptions and upweighting of follow-up after continuous treatment gave 326 deaths (including eight upweighted) in 14 214 total person-years (2·3 per 100 person-years) included in analyses. 85 (26%) deaths occurred within 12 weeks of ART initiation (11·8 per 100 person-years). Present co-trimoxazole prophylaxis halved mortality in the fi rst 12 weeks on ART, with no variation between participants on prophylaxis before screening (odds ratio [OR] 0·52, 95% CI 0·30-0·92, adjusted for baseline factors; p=0·02) versus those starting prophylaxis at the same time as ART (0·46, 0·25-0·84; p=0·01; heterogeneity p=0·69) or of variation between centres (heterogeneity p=0·35). Overall, using unweighted logistic regression and adjusting for baseline factors, but not controlling for time-dependent con founders, we showed that present co-trimoxazole use was associated with a 27% mortality reduction (0·73, 0·56-0·96; p=0·02; between-centre heterogeneity p=0·07).
As expected, mortality was higher in participants with low current CD4 cell count, haemoglobin concentration, or BMI, or with a WHO stage 3 or 4 event in the previous 4 weeks or any stage 3 or 4 event since randomisation (data not shown). These factors were also associated with increased probability of co-trimoxazole use, although extent of association varied between centres (data not shown). When we adjusted for these time-dependent predictors and randomisation to continuous treatment as factors within a regression model for mortality, the estimated OR for co-trimoxazole use was 0·62 (0·48-0·80; p=0·0002; between-centre heterogeneity p=0·50).
In a marginal structural model with inverse-probability treatment weights to control for time-dependent confounders, present prophylaxis reduced overall mortality risk by 35% (OR vs no present use 0·65, 0·50-0·85, p=0·001; table 2, fi gure). Benefi t did not diff er with randomised monitoring group (heterogeneity p=0·24). Furthermore, mortality risks did not diff er between participants who had stopped prophylaxis and never users, and benefi t did not vary with increasing time on cotrimoxazole in present users on ART (table 2, fi gure). Benefi t of present co-trimoxazole prophylaxis did, however, vary signifi cantly with time on ART (heterogeneity p=0·04 in a fl exible model for time on ART with cubic splines 20 ), falling from a 58% reduction in the fi rst 4 weeks on ART to a 5% reduction in weeks 68-72 (every additional 4 weeks on ART to 72 weeks increased estimated OR by 1·05 [1·01-1·09]; p=0·03), with no eff ect subsequently (p=0·67). When we categorised time on ART to show this variation, mortality reduction was greatest in the fi rst 12 weeks of treatment, sustained from 12-72 weeks, but not evident subsequently (heterogeneity p=0·02; fi gure). Adjustment for time on ART and time on co-trimoxazole simultaneously in present users showed that eff ect of time on ART was not confounded by duration of prophylaxis; similar mortality risk reductions were reported in the fi rst 72 weeks on ART in participants on co-trimoxazole for fewer than 24 consecutive weeks (OR 0·50, 0·34-0·73) and more than 24 consecutive weeks (0·48, 0·28-0·83), and we noted no reduction in mortality after 72 weeks on ART in either group (0·91 [0·47-1·77], heterogeneity before vs after 72 weeks, p=0·12; OR 0·96 [0·63-1·47], heterogeneity before vs after 72 weeks, p=0·05 respectively). Estimated average 5-year survival in DART participants starting ART with CD4 counts of 15 or 150 cells per μL increased by 5% and 2%, respectively, with co-trimoxazole prophylaxis (fi gure).
We estimated eff ects of prophylaxis on mortality from primary, secondary, or tertiary causes regarded as potentially preventable by co-trimoxazole (92 deaths: septicaemia [39], pneumonia [16] , severe brain syndrome as defi ned by the endpoint review committee [generally representing undiagnosed toxoplasmosis; 13], noncryptococcal meningitis [8] , diarrhoea [5] , malaria [4] , P jirovecii pneumonia [2] , acute febrile event [2] , toxoplasmosis [1] , chronic pulmonary disease [1] All participants began ART with a CD4 count lower than 200 cells per μL; 2576 (62%) person-years of followup in the fi rst 72 weeks and 2678 (27%) subsequently were spent with most recent CD4 count lower than 200 cells per μL. In the fi rst 72 weeks on ART, we estimated similar mortality reductions in participants with current CD4 counts lower than 200 cells per μL and 200 cells per μL or more on co-trimoxazole prophylaxis (fi gure). After 72 weeks on ART we noted no benefi t of present co-trimoxazole prophylaxis in participants with current CD4 counts lower than 200 cells per μL or 200 cells per μL or more (fi gure). Results were similar for deaths from causes regarded as potentially preventable by co-trimoxazole and for deaths from other causes. Alternative models including an additional CD4 count category of lower than 100 cells per μL (table 3) , more than 350 cells per μL, or allowing for a non-linear eff ect of CD4 cell count also provided no evidence for variation in eff ect of co-trimoxazole prophylaxis with current CD4 cell count. ART=antiretroviral therapy. PY=person-years. OR=odds ratio. *Deaths and person-years were excluded after randomisation to structured treatment interruptions in a substudy and upweighted after randomisation to continuous therapy. †OR are relative to no present use of co-trimoxazole prophylaxis and were estimated with historyadjusted marginal structural models, treating every 12-week follow-up visit as a new baseline, and considering mortality during the next 12 weeks (webappendix p 2). ‡CD4 cell count at last 12-week follow-up visit. Oesophageal candidosis, cryptococcosis, and extrapulmonary tuberculosis were the most common WHO stage 4 events, contributing 159 (31%), 115 (22%), and 108 (21%) fi rst events, respectively. Other diagnoses were individually less common. Only 22 (4%) stage 4 events were P jirovecii pneumonia (21 presumptive), of which 13 of 22 were on co-trimoxazole prophylaxis. We noted little evidence for a reduction in fi rst new WHO stage 4 events after ART initiation with co-trimoxazole (table 2). The marginal benefi t seen in past users is probably due to chance or incomplete adjustment for confounders in those stopping co-trimoxazole, and results of sensitivity analyses did not suggest that we had missed any benefi t in present users. Results did not diff er when oesophageal candidosis was excluded (data not shown). The eff ect of present prophylaxis on WHO stage 3 and 4 events, including recurrences of previous events as outcomes, was signifi cant, but this small eff ect did not vary with time on ART (table 2). Heterogeneity existed between centres (p=0·02), and we were unable to obtain consistent estimates of the eff ect of co-trimoxazole on pneumonia alone (which accounted for 280 [22%] fi rst WHO stage 3 or 4 events) across all four centres, suggesting variable diagnostic criteria or remaining unadjusted confounders.
In the fi rst 12 weeks on ART, CD4 cell count increased by a median 73 cells per μL and BMI by 0·76 kg/m² (0·00-1·60). Participants taking co-trimoxazole did not have greater CD4 cell count or BMI increases than did non-users in the fi rst 12 weeks or subsequently (table 4); estimated CD4 increases were slightly reduced with co-trimoxazole, probably because of some residual confounding (diff erence vs non-users -3 cells per μL [-12 to 6]; p=0·50). We showed no eff ect of co-trimoxazole on haemoglobin or platelet counts, and observed a small signifi cant reduction in neutrophil count in participants currently on co-trimoxazole after 72 weeks on ART (table 4) . Only 22 (3%) of 650 serious adverse events during the trial were judged to be related to co-trimoxazole (ten defi nite or probable, 12 uncertain relation, all haematological, rash, or hypersensitivity).
Harare has low malaria transmission. In Uganda, 1170 (53%) of 2200 participants had at least one malaria event, with 2362 events in total (260 upweighted; 27 per 100 person-years, 1119 [47%] diagnosed by microscopy, 1243 [53%] clinical). Present prophylaxis was associated with a 26% reduction in risk of fi rst new malaria episode in present users (table 2) , with similar estimates if more than one episode per person was included (data not shown) and a weakened eff ect when restricted to parasite-positive diagnoses (0·85 [0·65-1·11]; p=0·23). The reduction in malaria risk associated with co-trimoxazole was maintained throughout follow-up.
Discussion
In this large cohort of HIV-infected symptomatic African adults starting combination ART with low CD4 cell counts, we showed signifi cant reductions in mortality and malaria from daily co-trimoxazole prophylaxis in addition to benefi ts conferred by ART. Mortality reductions were striking in the fi rst 72 weeks of ART, with, in particular, early (0-12 weeks) mortality on ART being more than halved. The eff ect on malaria in Uganda was sustained beyond 72 weeks, consistent with reports that co-trimoxazole is an eff ective agent for malaria prophylaxis in semi-immune adults. >72 weeks on ART 0·3 (-11 to 11) 0·96 -0·01 (-0·20 to 0·18) 0·89 0·5 (-0·5 to 1·5) 0·32 -0·07 (-0·13 to -0·02) 0·009 2·1 (-2·8 to 7·0) 0·39
Data are eff ect of co-trimoxazole (95% CI). BMI=body-mass index. ART=antiretroviral therapy. *Estimated from unweighted normal regression models adjusting for centre, randomised monitoring group, randomisation year, age, sex, WHO stage, and ART prescription at randomisation together with baseline values of CD4 cell count, haemoglobin concentration, BMI, and a WHO stage 3 or 4 event in the 4 weeks before randomisation. For platelet and neutrophil outcomes, corresponding baseline values were also adjusted for. †p values for test of heterogeneity between centres were 0·68, 0·56, 0·21, 0·17, and 0·85, for CD4 cell count, BMI, and haemoglobin, and neutrophil and platelet concentrations, respectively. ‡Estimated from weighted repeated measures (every 12 weeks) normal regression models adjusting for length of time on ART with cubic splines, baseline covariates*, and time-varying values of CD4 cell count, haemoglobin concentration, BMI, WHO stage 3 or 4 event in the previous 4 weeks or since randomisation, and randomisation into a structured treatment interruption substudy (never, to continuous therapy). For neutrophil and platelet outcomes, corresponding time-varying values were also adjusted for. §p values for test of heterogeneity between centres were 0·07, 0·47, 0·21, 0·08, and 0·16. ¶By pattern of use no evidence was found for an eff ect with increasing time on co-trimoxazole prophylaxis or benefi t in past users compared with never users for any of the fi ve outcomes (data not shown). ||p values for test of heterogeneity between time periods were 0·01, 0·33, 0·43, 0·0004, and 0·81. Randomised trials are needed for the highest level of evidence, 22 but in their absence patients still have to be managed according to the best available evidence from other studies, particularly those that are large, well done, and have clear, plausible, and consistent results. Since our study was observational, identifi cation and appropriate adjustment for confounders is essential. Participants were in a randomised trial of management strategies, so the most important clinical and laboratory information used by clinicians for participant management was obtained systematically and prospect ively, and we were able to do several sensitivity analyses using diff erent models of inverse-probability treatment weights. In addition to the large cohort size, that we had four centres was invaluable for testing of these models since heterogeneity in eff ect of co-trimoxazole between centres suggested that confounders could remain. In models presented, results were consistent across centres and randomised monitoring strategies. Finally, censoring due to loss-to-follow-up was very low, and although we adjusted for censoring by using additional weighting, the eff ect was small. Since DART participants, who had advanced immunodefi ciency and symptomatic disease, had similar characteristics to those of most patients starting ART in rollout programmes in Africa, our fi ndings should be generalisable. Because our study used observational data we cannot guarantee that the results are free from bias, but with the systematic approaches used the possible direction and magnitude of any remaining bias are diffi cult to identify.
The survival benefi t conferred by co-trimoxazole was restricted to present use, with no variation in benefi t with use at or before enrolment or with increasing time on prophylaxis. The roughly 50% mortality risk reduction to 72 weeks after ART initiation is similar to that reported in ART-naive participants in randomised trials in resource-limited countries. 4, 5, 7, 10 Beyond 72 weeks on ART, we observed no mortality benefi ts. One limitation of our data was that most present use beyond 72 weeks was in individuals on long-term co-trimoxazole, so we cannot distinguish between time from ART initiation and duration of eff ects of co-trimoxazole use after this point. Trials in ART-naive participants have typically had little follow-up beyond 72 weeks, 4, 5, 7 although Nunn 10 reported a waning eff ect of co-trimoxazole prophylaxis with time, possibly related to falling adherence, in patients on treatment for concurrent tuberculosis. Stopping of cotrimoxazole prophylaxis after 72 weeks on ART might therefore be a reasonable strategy; randomised trials of diff erent durations of prophylaxis would inform this issue. Although risk of malaria will remain (as for exposed adults not infected with HIV/AIDS), malaria in semi-immune adults is generally not serious and is nonfatal, and co-trimoxazole is not the prophylaxis of choice against malaria. In DART, absolute risk of death was increased at low CD4 cell counts, but we noted no variation in mortality risk reductions according to most recent CD4 cell count. Results of ART-naive studies have shown no evidence for heterogeneity in eff ect of cotrimoxazole prophylaxis by baseline CD4 cell count on severe morbidity 5 or mortality.
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What co-trimoxazole prophylaxis is preventing, apart from malaria, is unclear from our data. In two trials of ART-naive adults, co-trimoxazole substantially reduced defi nitively diagnosed invasive bacterial disease with bacteraemia and malaria. 4, 5 In children, lower respiratory tract infections were signifi cantly reduced, but many died rapidly and most diagnoses were presumptive, 4, 23 as seen in other non-randomised co-trimoxazole studies in African adults. In DART we obtained through structured summaries as much data as possible for deaths, which were then independently reviewed by an endpoint review committee. In 55 (17%) unobserved deaths, no cause could be assigned; in the remainder, primary, secondary, and tertiary causes were assigned with emphasis on confi rmation of WHO 4 events because these were the primary endpoint. Although severe bacterial infections (as WHO stage 3 events) were systematically solicited and reported, they were not always microbiologically investigated. Thus, our data for cause of death cannot directly inform about mechanism of action, other than to note a substantial eff ect of co-trimoxazole prophylaxis on other causes, which could have been because of secondary sepsis.
Recurrent pneumonia diagnoses (individually reported as stage 3 events) have been reviewed by the endpoint review committee, because the revised WHO 2006 guidelines include two pneumonia episodes within 6 months as a stage 4 event. 24 However, insuffi cient events (n=13) were reported for a separate analysis. A key conclusion is that HIV studies in sub-Saharan Africa should document severe bacterial morbidity carefully, especially in patients with WHO stage 3 or 4 events. Although results of a recent study 25 suggested that almost all Mycobacterium tuberculosis isolates might retain invitro sensitivity to co-trimoxazole, we showed no evidence of an eff ect on pulmonary or extrapulmonary tuberculosis, similar to other WHO stage 3 or 4 events (data not shown).
Even if co-trimoxazole prophylaxis acts by partly or mainly reducing risk of mortality due to bacterial infections, why this mechanism should translate into mortality benefi ts before but not after 72 weeks is unclear. In particular, although one could postulate that severity of bacterial infections falls with increasing immune restoration, we did not show any variation in eff ect of cotrimoxazole by current CD4 cell count, and specifi cally no eff ect on deaths from causes regarded as potentially preventable by co-trimoxazole or other deaths in participants with low CD4 cell counts after 72 weeks. An alternative explanation, lent support by the absence of eff ect of prophylaxis on HIV-related disease progression and CD4 cell counts, is that although co-trimoxazole does not prevent HIV-related events, it might reduce mortality from them, irrespective of CD4 cell count. However, this explanation does not account for why the eff ect might occur before but not after 72 weeks from ART initiation. One hypothesis is that co-trimoxazole lowers bacterial load in the gut, thus reducing microbial translocation of bacterial lipopolysaccharides from the gastrointestinal tract into the bloodstream. Increased absorption of bacterial lipo polysaccharides raises immune activation, 26, 27 and co-trimoxazole use at ART initiation could increase and accelerate reductions in immune activation, especially before ART has itself aff ected immune activation. In a few small studies from resource-limited settings, investigators have reported high pre-ART immune activation, which then decreases only gradually during the fi rst 48 weeks of treatment. [28] [29] [30] Peripheral blood mononuclear cells were not stored in DART, so we cannot investigate this immune activation hypothesis further.
Mortality in patients accessing ART programmes in sub-Saharan Africa is very high in the fi rst year on treatment, with 8-26% of patients dying, [31] [32] [33] most in the fi rst 3-6 months. Even when baseline immunodefi ciency is allowed for, early mortality is several times higher in resource-limited settings than it is in high-income settings. 34 Although co-trimoxazole prophylaxis is recommended by WHO for symptomatic adults initiating ART in resource-limited settings, practice is variable and prophylaxis is often omitted. With no data from Africa, WHO recommendations were based on extrapolation from US studies, and many physicians have judged that co-trimoxazole would both be of little benefi t and have the potential to compromise adherence. In DART, adherence was high, and concerns that initiation of both cotrimoxazole and ART together might lead to unacceptably high rates of toxic eff ects are not substantiated by our data. The mortality benefi ts, safety, and tolerability, together with the low cost and simplicity of implementation, suggest that co-trimoxazole prophylaxis is cost eff ective and has a substantial public health eff ect. Our results reinforce WHO guidelines and provide strong motivation for provision of co-trimoxazole prophylaxis for at least 72 weeks to all adults starting combination ART in Africa.
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